Terms: = Breast cancer AND NDRG1, NDR1, 10397, ENSG00000104419, Q92597, RIT42, CMT4D, TARG1, HMSNL, GC4, RTP, TDD5, PROXY1, NMSL, CAP43 AND Treatment
37 results:
1. Integrated single-cell and bulk RNA sequencing analysis identifies a neoadjuvant chemotherapy-related gene signature for predicting survival and therapy in breast cancer.
Zhang X; Feng R; Guo J; Pan L; Yao Y; Gao J
BMC Med Genomics; 2023 Nov; 16(1):300. PubMed ID: 37996875
[TBL] [Abstract] [Full Text] [Related]
2. Proteomics on malignant pleural effusions reveals ERα loss in metastatic breast cancer associates with SGK1-ndrg1 deregulation.
Mayayo-Peralta I; Debets DO; Prekovic S; Schuurman K; Beerthuijzen S; Almekinders M; Sanders J; Moelans CB; Saleiro S; Wesseling J; van Diest PJ; Henrique R; Jerónimo C; Altelaar M; Zwart W
Mol Oncol; 2024 Jan; 18(1):156-169. PubMed ID: 37854018
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic analyses of genes associated with anoikis in breast cancer.
Cao J; Ma X; Zhang G; Hong S; Ma R; Wang Y; Yan X; Ma M
PeerJ; 2023; 11():e15475. PubMed ID: 37842046
[TBL] [Abstract] [Full Text] [Related]
4. Deciphering the mechanisms of action of progesterone in breast cancer.
Chakravorty G; Ahmad S; Godbole MS; Gupta S; Badwe RA; Dutt A
Oncotarget; 2023 Jul; 14():660-667. PubMed ID: 37395734
[TBL] [Abstract] [Full Text] [Related]
5. The role of the ndrg1 in the pathogenesis and treatment of breast cancer.
Zhao X; Richardson DR
Biochim Biophys Acta Rev Cancer; 2023 May; 1878(3):188871. PubMed ID: 36841367
[TBL] [Abstract] [Full Text] [Related]
6. Cellular senescence in the response of HR
Klapp V; Buqué A; Bloy N; Sato A; Yamazaki T; Zhou XK; Formenti SC; Galluzzi L; Petroni G
J Transl Med; 2023 Feb; 21(1):110. PubMed ID: 36765430
[TBL] [Abstract] [Full Text] [Related]
7. Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.
La Verde N; Damia G; Garrone O; Santini D; Fabi A; Ciccarese M; Generali DG; Nunzi M; Poletto E; Ferraris E; Cretella E; Scandurra G; Meattini I; Bertolini AS; Cavanna L; Collovà E; Romagnoli E; Rulli E; Legramandi L; Guffanti F; Bramati A; Moretti A; Cassano A; Vici P; Torri V; Farina G;
Breast Cancer Res; 2022 Oct; 24(1):71. PubMed ID: 36307826
[TBL] [Abstract] [Full Text] [Related]
8. Elucidating the pharmacological mechanism by which Si-Wu-Tang induces cellular senescence in breast cancer via multilevel data integration.
Zhao M; Pan B; He Y; Niu B; Gao X
Aging (Albany NY); 2022 Jul; 14(14):5812-5837. PubMed ID: 35859293
[TBL] [Abstract] [Full Text] [Related]
9. ndr1 increases NOTCH1 signaling activity by impairing Fbw7 mediated NICD degradation to enhance breast cancer stem cell properties.
Wang LL; Wan XY; Liu CQ; Zheng FM
Mol Med; 2022 May; 28(1):49. PubMed ID: 35508987
[TBL] [Abstract] [Full Text] [Related]
10. HJURP regulates cell proliferation and chemo-resistance via YAP1/ndrg1 transcriptional axis in triple-negative breast cancer.
Mao M; Jia Y; Chen Y; Yang J; Xu L; Zhang X; Zhou J; Li Z; Chen C; Ju S; Wang L
Cell Death Dis; 2022 Apr; 13(4):396. PubMed ID: 35459269
[TBL] [Abstract] [Full Text] [Related]
11. A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto breast cancer Trial.
Karn T; Meissner T; Weber KE; Solbach C; Denkert C; Engels K; Fasching PA; Sinn BV; Schrader I; Budczies J; Marmé F; Müller V; Holtrich U; Gerber B; Schem C; Young BM; Hanusch C; Stickeler E; Huober J; van Mackelenbergh M; Leyland-Jones B; Fehm T; Nekljudova V; Untch M; Loibl S
Clin Cancer Res; 2020 Apr; 26(8):1896-1904. PubMed ID: 31932495
[TBL] [Abstract] [Full Text] [Related]
12. Microarray and RNA in situ hybridization assay for recurrence risk markers of breast carcinoma and ductal carcinoma in situ: Evidence supporting the use of diverse pathways panels.
Evans MF; Vacek PM; Sprague BL; Stein GS; Stein JL; Weaver DL
J Cell Biochem; 2020 Feb; 121(2):1736-1746. PubMed ID: 31595577
[TBL] [Abstract] [Full Text] [Related]
13. Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader.
Tovell H; Testa A; Zhou H; Shpiro N; Crafter C; Ciulli A; Alessi DR
ACS Chem Biol; 2019 Sep; 14(9):2024-2034. PubMed ID: 31461270
[TBL] [Abstract] [Full Text] [Related]
14. TBX2 interacts with heterochromatin protein 1 to recruit a novel repression complex to EGR1-targeted promoters to drive the proliferation of breast cancer cells.
Crawford NT; McIntyre AJ; McCormick A; D'Costa ZC; Buckley NE; Mullan PB
Oncogene; 2019 Aug; 38(31):5971-5986. PubMed ID: 31253870
[TBL] [Abstract] [Full Text] [Related]
15. Up-regulation of the kinase gene
Godbole M; Togar T; Patel K; Dharavath B; Yadav N; Janjuha S; Gardi N; Tiwary K; Terwadkar P; Desai S; Prasad R; Dhamne H; Karve K; Salunkhe S; Kawle D; Chandrani P; Dutt S; Gupta S; Badwe RA; Dutt A
J Biol Chem; 2018 Dec; 293(50):19263-19276. PubMed ID: 30337371
[TBL] [Abstract] [Full Text] [Related]
16. The novel dithiocarbamate, DpdtC suppresses HER2-overexpressed cancer cells by up-regulating ndrg1 via inactivation of HER2-ERK 1/2 signaling.
Yang Y; Liu Y; Guo R; Fu Y; Zhang Z; Zhang P; Zhou P; Wang T; Huang T; Li X; Li C
Sci Rep; 2018 Feb; 8(1):3398. PubMed ID: 29467385
[TBL] [Abstract] [Full Text] [Related]
17. The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth.
Bago R; Sommer E; Castel P; Crafter C; Bailey FP; Shpiro N; Baselga J; Cross D; Eyers PA; Alessi DR
EMBO J; 2016 Sep; 35(17):1902-22. PubMed ID: 27481935
[TBL] [Abstract] [Full Text] [Related]
18. Antimetastatic effect of fluvastatin on breast and hepatocellular carcinoma cells in relation to SGK1 and ndrg1 genes.
Salis O; Okuyucu A; Bedir A; Gör U; Kulcu C; Yenen E; Kılıç N
Tumour Biol; 2016 Mar; 37(3):3017-24. PubMed ID: 26419593
[TBL] [Abstract] [Full Text] [Related]
19. WNT-1 inducible signaling pathway protein-1 enhances growth and tumorigenesis in human breast cancer.
Chiang KC; Yeh CN; Chung LC; Feng TH; Sun CC; Chen MF; Jan YY; Yeh TS; Chen SC; Juang HH
Sci Rep; 2015 Mar; 5():8686. PubMed ID: 25732125
[TBL] [Abstract] [Full Text] [Related]
20. Comprehensive MRI simulation methodology using a dedicated MRI scanner in radiation oncology for external beam radiation treatment planning.
Paulson ES; Erickson B; Schultz C; Allen Li X
Med Phys; 2015 Jan; 42(1):28-39. PubMed ID: 25563245
[TBL] [Abstract] [Full Text] [Related]
[Next]
